Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s): VYYRF

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > Cancel Early Christmas Present

<< Previous

Bullboard Posts

Next >>

Comment by biggdoggon Nov 28, 2024 1:50pm

40 Views

Post# 36335936

RE:RE:RE:Cancel Early Christmas Present

As far as I am concerned, I hope they raise just enough to get to revenue and not the full amount, the less dilution the better. I think Q1 the stock will be higher and more attractive as financing under the $10M market cap size is very difficult and most finance companies cant touch it. They need to get over $20M market cap to attract institutions. With some revenue everything changes. They should see a $3-4 million plus revenue in 2025.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”